Detection of polymorphisms in the human 5-lipoxygenase gene

An isolated nucleic acid molecule comprising a haplotype, wherein the haplotype comprises one or more of SEQ ID NO:

• 4, SEQ ID NO:
• 5, and SEQ ID NO:
• 6, one or more of SEQ ID NO:
• 7 and SEQ ID NO:
• 8, or the complements thereof, and wherein the nucleic acid molecule is a 5-LO gene.

A method for determining whether an asthma patient will be responsive to treatment with a 5-LO inhibitor, comprising

• a) obtaining a nucleic acid sample from the asthma patient;
• b) determining the presence of an allelic variant which differs from the reference sequence set forth in SEQ ID NO:1;
• and
• c) determining whether the asthma patient will be responsive to treatment with a 5-LO inhibitor based on the presence of an allelic variant which differs from the reference sequence set forth in SEQ ID NO:1, wherein the allelic variant comprises one or more nucleotide sequences selected from the group consisting of those set forth in SEQ ID NO:
• 4, SEQ ID NO:5, and SEQ ID NO:6, or the complement thereof.

A method for determining whether an asthma patient has a more or less severe asthma phenotype, comprising

• a) obtaining a nucleic acid sample from the asthma patient;
• b) determining the presence of an allelic variant which differs from the reference sequence set forth in SEQ ID NO:1;
• and
• c) determining whether the asthma patient has a more or less severe asthma phenotype based on the presence of an allelic variant which differs from the reference sequence set forth in SEQ ID NO:1, wherein the allelic variant comprises one or more nucleotide sequences selected from the group consisting of those set forth in SEQ ID NO:
• 4, SEQ ID NO:5, and SEQ ID NO:6, or the complement thereof.

A method for selecting the appropriate drug to administer to a patient who has asthma, comprising

• a) obtaining a nucleic acid sample from the patient;
• b) determining the presence of an allelic variant which differs from the reference sequence set forth in SEQ ID NO:1;
• and
• c) selecting the appropriate drug to administer to a patient who has an inflammatory disease or disorder based on the presence of an allelic variant which differs from the reference sequence set forth in SEQ ID NO:1, wherein the allelic variant comprises one or more nucleotide sequences selected from the group consisting of those set forth in SEQ ID NO:
• 4, SEQ ID NO:5, and SEQ ID NO:6, or the complement thereof.

A method of identifying a patient who is a candidate for effective treatment with a 5-LO inhibitor comprising the steps of:

• a) obtaining a nucleic acid sample from the patient;
• b) determining the presence of an allelic variant which differs from the reference sequence set forth in SEQ ID NO:1;
• and
• c) identifying a patient who is a candidate for effective treatment with a 5-LO inhibitor based on the presence of an allelic variant which differs from the reference sequence set forth in SEQ ID NO:1, wherein the allelic variant comprises one or more nucleotide sequences selected from the group consisting of those set forth in SEQ ID NO:
• 4, SEQ ID NO:5, and SEQ ID NO:6, or the complement thereof.